DRTS (DRTS) Stock Price & Analysis
DRTS (DRTS) fell 5.59% to USD 12.5 as of July 26, 2026 at 11:56 UTC, according to Nexqual real-time market data.
DRTS last closed at USD 13.24; the session ranged USD 12.39–13.5 on volume of 364,349 shares. Market capitalization is $1.13B, with a 52-week range of USD 2.87–14.11 (NCM). Source: Nexqual, July 26, 2026 at 11:56 UTC.
Key Statistics (as of July 26, 2026 at 11:56 UTC)
| Price | USD 12.5 |
|---|---|
| Change | ▼ 5.59% (down) |
| Previous Close | USD 13.24 |
| Open | USD 13.44 |
| Day Range | USD 12.39 – 13.5 |
| 52-Week Range | USD 2.87 – 14.11 |
| Volume | 364,349 shares |
| Market Cap | $1.13B |
| Exchange | NCM |
Technical Analysis (DRTS)
Nexqual's technical model rates DRTS "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 26, 2026 at 11:56 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.75 (neutral) |
| vs SMA50 | Above (USD 11.07) |
| MACD | 0.63 (positive) |
Analyst Ratings (DRTS)
Wall Street analysts rate DRTS "Buy" based on 5 analysts, with a mean price target of USD 14.2 (range USD 8–17), per Nexqual as of July 26, 2026 at 11:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 14.2 |
| High Target | USD 17 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (DRTS)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $192,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.12 ▼ miss |
| 2025-12-31 | USD -0.14 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.12 ▼ miss |
| 2025-06-30 | USD -0.13 vs est -0.11 ▼ miss |
Source: Nexqual, July 26, 2026 at 11:56 UTC.
Financials & Fundamentals (DRTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -90.51% |
| Debt / Equity | 20.68 |
| Current Ratio | 7.79 |
| Total Cash | $76.42M |
| Total Debt | $14.34M |
Source: Nexqual, July 26, 2026 at 11:56 UTC.
Financial Health Score (DRTS)
Nexqual rates DRTS's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 11:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $76M cash vs $14M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -91%, ROA -30.5% |
Ownership (DRTS)
| Insider Ownership | +31.23% |
|---|---|
| Institutional Ownership | +4.88% |
| Shares Outstanding | 90.33M |
| Float | 61.94M |
| Short % of Float | +4.80% |
Source: Nexqual, July 26, 2026 at 11:56 UTC.
Leadership (DRTS)
DRTS is led by Uzi Sofer (age 55), CEO & Chairman, per Nexqual as of July 26, 2026 at 11:56 UTC.
| CEO & Chairman | Uzi Sofer (age 55) |
|---|---|
| Chief Financial Officer | Raphi Levy (age 40) |
| Chief Technology Officer | Ronen Segal (age 52) |
| Chief Scientific Officer & Member of Scientific Advisory board | Yona Keisari (age 78) |
| Vice President of legal | Rebecca Becker |
Major Backers & Investors (DRTS)
Notable institutional backers of DRTS include HighTower Advisors, LLC, Aquamarine Financial (cayman) Ltd, ARK Invest, according to Nexqual as of July 26, 2026 at 11:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HighTower Advisors, LLC | 1.26% |
| Aquamarine Financial (cayman) Ltd | 1.04% |
| ARK Invest | 0.82% |
| Apella Capital, LLC | 0.55% |
| UBS Group AG | 0.41% |
| Daytona Street Capital LLC | 0.21% |
| NorthCoast Asset Management LLC | 0.21% |
| Mariner, LLC | 0.21% |
Source: Nexqual, July 26, 2026 at 11:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc | USD 11.32 | ▼ 6.29% |
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.6 | ▼ 7.38% |
| HOVR | New Horizon Aircraft Ltd. | USD 1.78 | ▼ 6.81% |
| GANX | Gain Therapeutics, Inc. | USD 1.75 | ▼ 4.89% |
| NVCT | Nuvectis Pharma, Inc. | USD 19.31 | ▲ 0.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:56 UTC. This page is informational and not investment advice.